Resonance Health Ltd · ASX:RHT

Resonance Health — Shareholder Meeting (November 2012)

14 slides from Resonance Health's shareholder meeting presentation, Nov 15, 2012

1. Slide 1: Annual General Meeting – Resolutions

   Resonance Health Ltd For personal use only Annual General Meeting 15 November 2012 Resolutions

2. Slide 2: Proxy Results – Resolution 1: Adoption of the Remuneration Report

   Proxy Results Resolution 1 For personal use only Adoption of the Remuneration Report For Against Abstaining Discretionary Res 1 7,417,031 1,414,381 3,815,290 9,245,075

3. Slide 3: Proxy Results – Resolution 2: Re-election Dr Timothy St Pierre

   Proxy Results Resolution 2 For personal use only Re-election Dr Timothy St Pierre For Against Abstaining Discretionary Res 2 12,564,439 82,263 0 9,245,075

4. Slide 4: Annual General Meeting – Ms Liza Dunne, Managing Director

   Resonance Health Ltd For personal use only Annual General Meeting 15 November 2012 Ms Liza Dunne Managing Director

5. Slide 5: FerriScan – gold standard diagnostic tool for measuring iron overload

   FerriScan – gold standard diagnostic tool for measuring iron overload _______________________________________________________________________________________________________ For personal use only  “…..spin-echo imaging as proposed by St. Pierre et al. currently remains the gold standard.” 1  “…..t

6. Slide 6: FerriScan sales growth

   FerriScan sales growth _________________________________________________________________________________________________ For personal use only FerriScan sales volumes and % growth year-on-year 14% 4000 14%  36% growth in the UK 3500 36%  28% growth in the USA 3000 36% 2500 2000 1500 1000 500 0 200

7. Slide 7: Growing FerriScan customer base

   Growing FerriScan customer base _________________________________________________________________________________________________  FerriScan became available in Scotland, Ireland, Switzerland, For personal use only Brazil, Argentina, Colombia, Mexico and Venezuela  There are now 44 FerriScan facil

8. Slide 8: FerriScan

   FerriScan ______________________________________________________________________________________________  US and EU markets continue to show strong growth • 36% growth in the UK For personal use only • 28% growth in the US  Some FerriScan facilities are using the Company’s Cardiac T2* service for

9. Slide 9: Financial Results

   Financial Results _________________________________________________________________________________________________ For personal use only  Revenue down 11% due to decline in clinical trial services for iron overload therapy  Strong Australian dollar negatively impacted revenue - 80% of revenue rec

10. Slide 10: Growth through R&D and collaborations

    Growth through R&D and collaborations _________________________________________________________________________________________________ For personal use only Proof of U.S. On Reimbur- Research concept Validate sement 510K Market (Canada/ FerriScan® (liver iron assessment) UK) Cardiac T2* (cardiac ir

11. Slide 11: HepaFat-Scan

    HepaFat-Scan™ _______________________________________________________________________________________________  Large non-alcoholic fatty liver disease (NAFLD) market  Approximately 30% of the US population has fatty liver disease For personal use only  NAFLD is the most common cause of liver dise

12. Slide 12: Liver fibrosis project

    Liver fibrosis project _________________________________________________________________________________________________  Pathologist assessment of liver fibrosis will be compared to MRI assessment of liver fibrosis For personal use only  Patient recruitment completed and all patient measurements

13. Slide 13: Summary

    Summary _________________________________________________________________________________________________  Strong growth in FerriScan sales volumes For personal use only  Positive US reimbursement progress  Potential FDA relabeling of FerriScan – possible implications for expanding role with phar

14. Slide 14: Thank You

    For personal use only Thank You

Resonance Health — Shareholder Meeting (November 2012) on 6ix